Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05141019 · ClinicalTrials.gov registry record · NA
Trial of Preemptive Pharmacogenetics in Underserved Patients
A NA study of Pharmacogenetic Testing and Use of Prescription Medications, sponsored by University of Florida.
- Active
- Registry status
- NA
- Development phase
- 492
- Enrollment target
- 1
- Study location
NCT05141019: Active NA study of Pharmacogenetic Testing and Use of Prescription Medications, sponsored by University of Florida.
NCT05141019 is a NA study of Pharmacogenetic Testing and Use of Prescription Medications that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 492 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05141019, a NA study of Pharmacogenetic Testing and Use of Prescription Medications, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 492 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed research is relevant to human health because preemptive clinical pharmacogenetic testing may improve the personalization of drug therapy which should improve patient outcomes. Better understanding of the effectiveness and feasibility of preemptive clinical pharmacogenetic testing will inform when and how this innovative healthcare technology is implemented into clinical care. To ensure equitable dissemination in all patient populations, such data is also needed in racial minorities and other traditionally underserved populations. The combined proposed research are relevant to the parts of the NIH's mission pertaining to protecting and improving health and developing scientific human resources that will ensure the Nation's capability to prevent and treat disease.
Primary Outcome
The primary feasibility outcome will be change in patient treatment satisfaction between baseline and 12 months after enrollment into the study. This patient-reported outcome will be measured via the TSQM. The TSQM is a validated tool that assesses three medication-related domains (effectiveness, side effects, and convenience) to synthesize a global satisfaction score. Both global satisfaction and scores from individual domains will be analyzed.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Panel-based pharmacogenetic genotyping
Study Locations (1)
Florida
- UF Health at the University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05141019 still lists
NCT05141019 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Pharmacogenetic Testing appearing as the primary indexed condition, and to 1 intervention - of which Panel-based pharmacogenetic genotyping is the first listed.
NCT05141019 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05141019 about?
NCT05141019 is a clinical study titled "Trial of Preemptive Pharmacogenetics in Underserved Patients". This proposed research is relevant to human health because preemptive clinical pharmacogenetic testing may improve the personalization of drug therapy which should improve patient outcomes. Better understanding of the effectiveness and feasibility of preemptive clinical pharmacogenetic testing will ...
What is the current status of trial NCT05141019?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 492 participants. The study started on 2022-08-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05141019 study?
This clinical trial studies the following conditions: Pharmacogenetic Testing, Use of Prescription Medications.
What interventions are being tested in trial NCT05141019?
The interventions under investigation include: Panel-based pharmacogenetic genotyping (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05141019?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05141019 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05141019's enrollment target sits among peer trials
492 213th of 2000 higher than 1,786 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI